Deutetrabenazine (Austedo)

ORAL ADMINISTRATION

Indications for Prior Authorization:

  • Treatment of chorea associated with Huntington's disease

Patients must meet the following criteria for the indication(s) above:

  • Prescribed by or in collaboration with a specialist (neurologist), AND
  • 18 years or older, AND
  • Diagnosis of chorea associated with Huntinton's disease, as indicated by characteristic motor examination features and genetic testing (i.e., an expanded HTT CAG repeat sequence greater than or equal to 36); AND
  • The member is ambulatory, AND
  • The member does not have any of the following:
    • Suicidal, or untreated/inadequately treated depression (a score of greater than or equal to 11 on the depression subscale of the Hospital Anxiety and Depression scale (HADS));
    • Hepatic impairment
    • Those taking MAOIs, reserpine, or tetrabenazine; AND
  • Tried and failed both tetrabenazine and amantadine

Reauthorization criteria:

  • Chorea symptoms have improved or stabilized; AND
  • The member does not have any of the following:
    • Suicidal, or untreated/inadequately treated depression (a score of greater than or equal to 11 on the depression subscale of the Hospital Anxiety and Depression scale (HADS));
    • Hepatic impairment
    • Those taking MAOIs, reserpine, or tetrabenazine; AND
  • Precautions include:
    • Neuroleptic malignant syndrome (NMS): discontinue if this occurs
    • Akathisia, agitiation, restlessness, and parkonism: reduce dose or discontinue if this occurs
    • Sedation/somnolence: may impair the patient's ability to drive or operate heavy machinery

Dosing:

  • Initial: 6mg once daily.  Titrate up at weekly intervals by 6mg per day to a tolerated dose that reduces chorea, up to a maximum recommended daily dosing of 48mg (24mg twice daily)
  • Administer total daily dosages of 12mg or above in two divided doses
  • Administer with food
  • Swallow tablets whole; do not chew, crush or break
  • If switching from tetrabenazine, discontinue tetrabenazine and initiate Austedo the following day
  • Mazimum recommended dosage in poor CYP2D6 metabolizers is 36mg per day (18mg twice daily)

Approval:

  • Initial: 3 months
  • Renewal: 1 year

Last review date: June 12, 2017

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar